LibrarianMeg said:

I have been dealing with this for about 6 months now, and what I have found is that individual respo

I respect LibrarianMeg perspective but I think this oversimplifies things a bit. Re: Japan GLP-1 access navigating — the subgroup analyses show meaningful heterogeneity.

I am not saying LibrarianMeg wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.

Relevant to Japan GLP-1 access navigating — here is my latest bloodwork comparison:

Key improvements: A1C 7.6% → 5.5%, triglycerides 201 → 101 mg/dL, hsCRP 8.0 → 1.3 mg/L. All on tirzepatide for 17 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you ingrid_STO! This is incredibly helpful. Taking this to my next appointment. 🙏

Slightly tangential to Japan GLP-1 access but JessicaM_2024 reminded me — does anyone have experience combining this with metformin?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Great discussion, everyone. Just a reminder to keep things civil and evidence-based.

Thread quality is excellent — keep it up. 👍